

# Plasma Free H<sub>2</sub>S Levels are Elevated in Patients With Cardiovascular Disease

Elvis A. Peter, MD; Xinggui Shen, PhD; Shivang H. Shah, MD, MPH; Sibile Pardue, MS; John D. Glawe, MS; Wayne W. Zhang, MD; Pratap Reddy, MD; Nuri I. Akkus, MD; Jai Varma, MD; Christopher G. Kevil, PhD

**Background**—Hydrogen sulfide (H<sub>2</sub>S) has been implicated in regulating cardiovascular pathophysiology in experimental models. However, there is a paucity of information regarding the levels of H<sub>2</sub>S in health and cardiovascular disease. In this study we examine the levels of H<sub>2</sub>S in patients with cardiovascular disease as well as bioavailability of nitric oxide and inflammatory indicators.

**Methods and Results**—Patients over the age of 40 undergoing coronary or peripheral angiography were enrolled in the study. Ankle brachial index (ABI) measurement, measurement of plasma-free H<sub>2</sub>S and total nitric oxide (NO), thrombospondin-1 (TSP-1), Interleukin-6 (IL-6), and soluble intercellular adhesion molecule-1 (sICAM-1) levels were performed. Patients with either coronary artery disease alone (n=66), peripheral arterial disease (PAD) alone (n=13), or any vascular disease (n=140) had higher plasma-free H<sub>2</sub>S levels compared to patients without vascular disease (n=53). Plasma-free H<sub>2</sub>S did not distinguish between disease in different vascular beds; however, total NO levels were significantly reduced in PAD patients and the ratio of plasma free H<sub>2</sub>S to NO was significantly greater in patients with PAD. Lastly, plasma IL-6, ICAM-1, and TSP-1 levels did not correlate with H<sub>2</sub>S or NO bioavailability in either vascular disease condition.

**Conclusions**—Findings reported in this study reveal that plasma-free H<sub>2</sub>S levels are significantly elevated in vascular disease and identify a novel inverse relationship with NO bioavailability in patients with peripheral arterial disease.

**Clinical Trial Registration**—URL: <http://www.clinicaltrials.gov>. Unique identifier: NCT01407172. (*J Am Heart Assoc.* 2013;2:e000387 doi: 10.1161/JAHA.113.000387)

**Key Words:** coronary artery disease • hydrogen sulfide • nitric oxide • peripheral arterial disease

Nitric oxide (NO) and hydrogen sulfide (H<sub>2</sub>S) are now well-established gasotransmitters with protean functions in human biology including specific roles in cardiovascular physiology that continue to be elucidated. Both of these gaseous mediators are synthesized through enzymatic and nonenzymatic pathways. NO production classically occurs in an enzymatic manner via the nitric oxide synthase (NOS) isoenzymes with nonenzymatic reduction of nitrite/nitrate serving as alternative pathways.<sup>1</sup> Likewise, H<sub>2</sub>S is also produced by 3 principal enzymes including cystathionine  $\gamma$ -lyase (CGL/CSE), cystathionine  $\beta$ -synthase (CBS), and

3-mercaptopyruvate transferase (3-MST),<sup>2,3</sup> with nonenzymatic generation via glutathione and other sulfane sulfur redox pathways.<sup>4</sup> Biological effects of NO and H<sub>2</sub>S occur predominantly through small molecule interactions and posttranslational protein thiol modifications.<sup>5</sup> Moreover, studies have suggested a role for H<sub>2</sub>S in vasodilation as an alternative to nitric oxide; as well as regulation of atherogenesis at the cellular and molecular level.<sup>6–8</sup> Importantly, reports have suggested that H<sub>2</sub>S can affect endothelial nitric oxide synthase (eNOS) expression and function while also increasing nitrite anion reduction to NO, thereby establishing an alternate pathway for regulating NO bioavailability.<sup>9,10</sup> However, no information currently exists regarding biochemical relationships between NO and H<sub>2</sub>S in clinical settings.

Precise understanding of H<sub>2</sub>S pathophysiology has been impeded by controversies in its measurement. The most widely used assay, the methylene blue method, lacks specificity and is subject to various sources of error in the measurement of bioavailable free H<sub>2</sub>S.<sup>11–13</sup> These issues aside, there still remains a paucity of information on clinical H<sub>2</sub>S levels in humans associated with cardiovascular disease. The few papers that have explored this have been hampered

From the Section of Cardiology (E.A.P., S.H.S., P.R., N.I.A., J.V.), and the Departments of Surgery (W.W.Z.) and Pathology (X.S., S.P., J.D.G., C.G.K.), Louisiana State University Health Shreveport, Shreveport, LA.

**Correspondence to:** Christopher G. Kevil, PhD, Department of Pathology, 1501 King's Highway, Shreveport, LA 71130. E-mail: ckevil@lsuhsc.edu  
Received June 21, 2013; accepted September 6, 2013.

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

by the use of older methods and associated limitations.<sup>14</sup> Recent advances in H<sub>2</sub>S detection methods have identified accurate and reliable analytical approaches with which to measure free bioavailable H<sub>2</sub>S, including the ability to distinguish differences in levels amongst various mutant, germ free, and wild type animals.<sup>12,15,16</sup> Using these analytical measurement methods, we have obtained insight into plasma-free H<sub>2</sub>S levels in young healthy adults, but such information in patients with cardiovascular disease remains unknown.<sup>17</sup> In an effort to understand the relationship between bioavailable free H<sub>2</sub>S and NO in patients with and without vascular disease, we undertook an unbiased observational clinical study measuring these molecules in plasma from patients presenting for coronary or peripheral angiography at our institution. Additionally, we also measured plasma thrombospondin-1 (TSP-1), interleukin-6 (IL-6) and soluble intercellular adhesion molecule-1 (sICAM-1) levels. Here we report changes in plasma-free H<sub>2</sub>S levels that are differentially associated with NO depending on cardiovascular disease status.

## Methods

### Study Design

Our clinical study complied with the declaration of Helsinki and was approved by the institutional review board of the Louisiana State University Health Sciences Center at Shreveport (LSUHSC-S) and was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov), NCT 01407172.

Patients over the age of 40 undergoing cardiac catheterization or peripheral angiogram via a major arterial approach at the LSUHSC-S cardiac catheterization laboratory or vascular surgery suite were enrolled in the study. Our protocol took advantage of the fact that we broadly enrolled patients with suspected cardiovascular disease that was either confirmed or ruled out by angiography. The patients presented for angiography for the usual clinically accepted indications including cases of coronary angiography, unstable angina, non-ST elevation myocardial infarction, and stable angina. Similarly, peripheral angiography was performed for claudication and critical limb ischemia. All patients had the measurement of the ankle brachial index performed by the straight wrapping method, as currently recommended,<sup>18</sup> with an 8-MHz hand-held Doppler by a single physician operator. ABI measurement was performed prior to angiography in all patients. In this way, we were able to recruit and enroll patients in an unbiased manner and then separate them into distinct disease cohorts as discussed below. A total of 271 patients were enrolled in the study with 78 patients excluded due to various reasons including non-compressible vessels (at the time of study initiation defined as an ABI >1.3), excess


number of enrolled nonperipheral artery disease patients beyond IRB-approved numbers allowed for further study, sample processing quality control failures (eg, exceeding collection tube incubation time or specimen hemolysis), or other issues (eg, cancellation of planned procedure). A total of 193 patients were studied and, based on the ankle brachial index or known peripheral artery disease (PAD) status, were classified as follows:

- 1 Patients without PAD as defined by ABI >0.9 and <1.3.
- 2 Patients with PAD as defined by an ABI <0.9 or documented PAD on peripheral angiogram or with prior peripheral arterial interventions.

The above groups were then divided according to the presence or absence of coronary artery disease (CAD) on the basis of their coronary angiogram using the currently accepted definitions for the same (ie, presence of >50% stenosis in at least 1 major epicardial coronary artery of size greater 2 mm).<sup>19</sup> In a few cases, coronary angiography could not be performed and CAD diagnosis was performed on the basis of medical history using the same criterion or history of prior myocardial infarction. Figure 1 illustrates the flow chart of cohort assignments along with the number of subjects per cohort.

### Exclusion Criteria

Patients were excluded from the study if they were unable to provide informed consent, were enrolled in another clinical trial requiring the use of experimental therapeutic agents, or were pregnant or nursing. Additional exclusion criteria included patients with nonatherosclerotic PAD (eg, Buerger's disease) and those with ABI >1.3 (indicative of noncompressible vessel needing further evaluation to diagnose PAD) unless they had documented known PAD. Patients presenting with ST elevation myocardial infarction or cardiogenic shock were also excluded to avoid delays in care.




**Figure 1.** Study organization flow chart. A total of 193 patients were used for analysis, including a total of 74 PAD patients along with 119 non-PAD patients who were subsequently diagnosed with or without CAD after cardiac catheterization. CAD indicates coronary artery disease; PAD, peripheral artery disease.

## Historical Data and Blood Collection

Medical record data were collected and patient interviews were conducted to assess for the presence of traditional risk factors (hypertension, dyslipidemia, diabetes, obesity, smoking, and racial and sex classification). Under routine aseptic conditions, a femoral or radial vascular access sheath was placed at the operator's discretion for the performance of the procedure. Twelve milliliters of blood was then collected into a sterile 20-mL syringe after bleed back to ensure that no contamination with saline used to flush catheters occurred. This sample of blood was then directly injected into 2 plastic 6-mL lithium heparin vacutainer tubes. Lithium heparin collection tubes were selected after initial experiments using healthy blood donors who demonstrated decreased hemolysis compared to ethylenediaminetetraacetic acid (EDTA) collections tubes, a phenomenon that has also been previously demonstrated by others particularly if the EDTA tube is incorrectly filled<sup>20</sup> (Figure 2A and 2B). After inversion 4 to 5 times to ensure adequate mixing with the anticoagulant, the tube was placed on ice and transported to the research lab. To ensure consistency across samples, specimens were centrifuged at 9 minutes after collection for 4 minutes at a RCF (relative centrifugal force) of 1500g.

## Measurement of Plasma Free H<sub>2</sub>S and Total Nitric Oxide

Plasma samples were analyzed for H<sub>2</sub>S as previously described.<sup>12</sup> Briefly, plasma free H<sub>2</sub>S was measured by reversed-phase high-performance liquid chromatography (RP-HPLC) after derivatization with excess monobromobimane (MBB) to form the stable sulfide-dibimane derivative. Thirty microliters of plasma was mixed with 70  $\mu$ L of 100-mmol/L Tris-HCl buffer (pH 9.5, 0.1 mmol/L DTPA), followed by addition of 50  $\mu$ L of 10-mmol/L MBB. The reaction was stopped after 30 minutes by adding 50  $\mu$ L of 200-mmol/L 5-sulfosalicylic acid, and then the sample was centrifuged and the supernatant analyzed using a Shimadzu Prominence HPLC with fluorescence detection ( $\lambda_{ex}$ : 390 nm and  $\lambda_{em}$ : 475 nm) and an Eclipse XDB-C18 column. A separate aliquot of plasma was placed in NO preservation solution (800 mmol/L potassium ferricyanide, 17.6 mmol/L N-ethylmaleimide, and 6% nonidet P40) for tri-iodide NO chemiluminescent analysis as we have previously reported.<sup>21</sup> All plasma levels of H<sub>2</sub>S or NO were quantified based on sulfide dibimane and sodium nitrite standard curves, respectively. Finally, a third plasma aliquot was used for enzyme-linked immunosorbent assay (ELISA) measurement of thrombospondin-1 (TSP-1), IL-6 and sICAM-1 levels using the commercially available ELISA assays (R&D



**Figure 2.** Effect of blood collection tubes on plasma hydrogen sulfide (H<sub>2</sub>S) levels. Venous blood was collected from healthy volunteers in either lithium heparin or ethylenediaminetetraacetic acid (EDTA) vacutainer collection tubes. A, reports the differences in plasma free H<sub>2</sub>S between the different collection tubes vs lysed red blood cells (RBC) (\*\**P*<0.01 vs lithium heparin collection tubes). B, illustrates amount of cell free hemoglobin measured using the Drabkin assay in plasma from blood collected in various tubes vs lysed red blood cells (\*\**P*<0.01 vs lithium heparin collection tubes).

Systems, Cayman Chemicals, and Thermo Scientific, respectively) per the manufacturer's instructions.

## Statistical Analysis

Based on our initial analytical measurements of plasma-free H<sub>2</sub>S levels in mice and humans,<sup>17</sup> a power analysis was performed (to 0.8) to identify the number of subjects needed assuming a 15% difference among subjects with or without PAD as well as a 5% drop out rate. This yielded 110 subjects per cohort for a total of 220 subjects. Data were analyzed with Statistical Package for Social Sciences version 16.0 (SPSS for Windows 7). A *P* value of <0.05 was required to achieve statistical significance. Linear regression analysis, independent sample *t* test, chi square test, and Spearman and Pearson's correlation analysis were performed based on the normality of the data and type of variable as noted below in the results section.

## Results

### Demographics and Baseline Characteristics

Clinical characteristics of the enrolled patients were analyzed on the basis of the presence and absence of vascular disease (ie, patients with either or both PAD and CAD versus those without vascular disease [Table 1]). These data report phenotypic characteristics and associated percentages of the cohorts including race, sex, and traditional cardiovascular risk factors. Category percentages per cohort are listed in Table 1. Table 2 also lists the prevalence of pharmaceutical agents that were taken by each patient cohort.

### Plasma Free H<sub>2</sub>S and Vascular Disease

Linear regression analysis and independent sample *t* test were employed to examine the relationship between H<sub>2</sub>S

bioavailability and specific cardiovascular disease status. Plasma-free H<sub>2</sub>S levels in patients with either vascular disease (mean 441.0 nmol/L) were significantly elevated compared to patients without vascular disease (mean 368.5 nmol/L, *P*=0.01) (Table 3). Importantly, elevated H<sub>2</sub>S levels seen in patients with either vascular disease compared to those without vascular disease was independent of traditional risk factors including age, race, gender, and history of diabetes mellitus (DM) hypertension (HTN), hyperlipidemia, smoking, or obesity. Similarly, free-plasma H<sub>2</sub>S levels in patients with PAD alone (mean 514.4 nmol/L, *P*=0.007) or CAD alone (mean 443.8 nmol/L, *P*=0.02) were significantly greater than patients without either vascular disease (mean 368.5 nmol) (Table 3). However, differences in plasma-free H<sub>2</sub>S levels between patients with CAD alone versus PAD alone were not significant (*P*=0.18). Thus, plasma-free H<sub>2</sub>S alone was not able to discriminate between different forms of vascular disease.

**Table 1.** Patient Demographic Characteristics

	Diagnosis							
	No Vascular Disease (53 Patients)		Any Vascular Disease (140 Patients)		CAD Alone (66 Patients)		PAD Alone (13 Patients)	
	Mean±SD	Count (N%)	Mean±SD	Count (N%)	Mean±SD	Count (N%)	Mean±SD	Count (N%)
Age, y	53 ± 8.6		57 ± 8.5		55 ± 8.7		58 ± 8.0	
Gender								
Male		15 (28.3)		85 (60.7)		39 (59.1)		9 (69.2)
Female		38 (71.7)		55 (39.3)		27 (40.9)		4 (30.8)
Race								
Nonblack		14 (26.4)		66 (47.1)		38 (57.6)		5 (38.5)
Black		39 (73.6)		74 (52.9)		28 (42.4)		8 (61.5)
Dyslipidemia								
No		32 (60.4)		38 (27.1)		19 (28.8)		4 (30.8)
Yes		21 (39.6)		102 (72.9)		47 (71.2)		9 (69.2)
DM								
No		36 (67.9)		85 (60.7)		38 (57.6)		9 (69.2)
Yes		17 (32.1)		55 (39.3)		28 (42.4)		4 (30.8)
HTN								
No		10 (18.9)		10 (7.1)		3 (4.5)		2 (15.4)
Yes		43 (81.1)		130 (92.9)		63 (95.5)		11 (84.6)
Obesity								
Nonobese		17 (32.1)		68 (48.6)		28 (42.4)		8 (61.5)
Obese		36 (67.9)		72 (51.4)		38 (57.6)		5 (38.5)
Smoking								
Nonsmoker		37 (69.8)		70 (50.0)		35 (53.0)		4 (30.8)
Smoker		16 (30.2)		70 (50.0)		31 (47.0)		9 (69.2)

CAD indicates coronary artery disease; DM, diabetes mellitus; HTN, hypertension; PAD, peripheral artery disease; SD, standard deviation.

**Table 2.** Patient Medications Taken

Home Medications	Diagnosis							
	No Vascular Disease		Any Vascular Disease		CAD Alone		PAD Alone	
	Count	N%	Count	N%	Count	N%	Count	N%
<b>Aspirin</b>								
No	24	45.3	42	30.0	18	27.3	3	23.1
Yes	29	54.7	98	70.0	48	72.7	10	76.9
<b>Clopidogrel</b>								
No	46	86.8	92	65.7	46	69.7	12	92.3
Yes	7	13.2	48	34.3	20	30.3	1	7.7
<b>Other Antiplatelet</b>								
No	53	100.0	138	98.6	65	98.5	12	92.3
Yes	0	0.0	2	1.4	1	1.5	1	7.7
<b>β Blocker</b>								
No	21	39.6	43	30.7	18	27.3	10	76.9
Yes	32	60.4	97	69.3	48	72.7	3	23.1
<b>ACE/ARB</b>								
No	28	52.8	38	27.1	20	30.3	5	38.5
Yes	25	47.2	102	72.9	46	69.7	8	61.5
<b>Statin</b>								
No	28	52.8	40	28.6	18	27.3	5	38.5
Yes	25	47.2	100	71.4	48	72.7	8	61.5
<b>Cilostazol</b>								
No	53	100.0	137	97.9	66	100.0	12	92.3
Yes	0	0.0	3	2.1	0	0.0	1	7.7

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; PAD, peripheral artery disease.

### Free H<sub>2</sub>S and Smoking Status

An independent sample *t* test showed that patients who were current smokers had significantly elevated free H<sub>2</sub>S levels (mean 452.28 nmol/L, *P*=0.03) as compared to those who were not current smokers (mean 396.10 nmol/L). However, linear regression analysis revealed that when controlled for the presence of vascular disease the difference between smokers and non-smokers was not significant (*P*=0.073). A 1-way analysis of covariance (ANCOVA) between subjects was done to examine the effect of smoking on the relationship

between H<sub>2</sub>S and vascular disease that revealed that patients with vascular disease had significantly higher adjusted H<sub>2</sub>S levels (mean±SE=438.54±14.73) as compared to the patients without vascular disease (mean±SE=375.15±24.11, *F*(1,190)=4.97, *P*=0.027).

### Inflammatory Indicators and H<sub>2</sub>S Levels

Several inflammatory markers including sICAM-1, IL-6, and TSP-1 reported to participate in cardiovascular disease were examined. There was no significant difference noted

**Table 3.** Plasma-Free H<sub>2</sub>S and Total NO Levels in Vascular Disease

	No Vasc Disease, n=53	Any Vasc Disease, n=140	CAD Alone, n=66	PAD Alone, n=13
Plasma free H <sub>2</sub> S, nmol/L	368.53±20.87	441.04±15.40 ( <i>P</i> =0.010)	443.89±21.67 ( <i>P</i> =0.020)	514.48±62.05 ( <i>P</i> =0.007)
Total NO levels, nmol/L	64.71±1.12	64.71±1.07 ( <i>P</i> =0.997)	61.56±1.09 ( <i>P</i> =0.743)	38.86±1.20 ( <i>P</i> =0.034)

All data are reported as mean±standard error of the mean. *P* value is compared to no vascular disease group. CAD indicates coronary artery disease; H<sub>2</sub>S, hydrogen sulfide; NO, nitric oxide; PAD, peripheral artery disease.

**Table 4.** Plasma sICAM, IL6, and TSP-1 Levels in Vascular Disease

	No Vasc Disease, n=53	Any Vasc Disease, n=140	CAD Alone, n=66	PAD Alone, n=13
sICAM, ng/mg	365.04±1.05	389.16±1.03 ( <i>P</i> =0.324)	375.40±1.04 ( <i>P</i> =0.704)	378.80±1.16 ( <i>P</i> =0.766)
IL6, ng/mg	12.83±1.20	17.53±1.12 ( <i>P</i> =0.156)	13.24±1.17 ( <i>P</i> =0.900)	25.89±1.37 ( <i>P</i> =0.093)
TSP-1, ng/mg	40.95±2.25	37.09±1.37 ( <i>P</i> =0.143)	37.33±1.95 ( <i>P</i> =0.230)	32.43±4.05 ( <i>P</i> =0.093)

All data are reported as mean±standard error of the mean. *P* value is compared to no vascular disease group. CAD indicates coronary artery disease; IL-6, interleukin-6; PAD, peripheral artery disease; sICAM, soluble intercellular adhesion molecule-1; TSP-1, thrombospondin-1.


amongst the various inflammatory markers between the patient cohorts, although increasing trends for IL-6 was noted in patients with PAD alone (Table 4). Additionally, Pearson correlation analysis did not reveal any significant association between plasma-free H<sub>2</sub>S and levels of IL-6, sICAM, or TSP-1.

### NO and Vascular Disease

Plasma NO levels have been reported to be inversely related to the number of cardiovascular risk factors such that the greater the number of risk factors the lower the plasma NO levels.<sup>22</sup> Interestingly, we found that patients with no vascular disease had considerably lower plasma NO levels (mean=64.7 nmol/L) compared to previously reported “normal” NO levels of healthy adults (≈150 to 300 nmol/L).<sup>22</sup> However, our findings are not surprising as patients without clinically diagnosed vascular disease still had numerous risk factors, as noted in Table 1, that are known to contribute to endothelial cell dysfunction and reduced NO levels.<sup>22</sup> Interestingly, linear regression analysis revealed that plasma total NO levels were only significantly lower in patients with PAD alone (mean 38.86 nmol/L, *P*=0.034) compared to subjects without vascular disease. Together, these data highlight that plasma NO bioavailability was considerably diminished in our study subjects compared to previously reported normal healthy subjects<sup>22</sup> and that patients with PAD alone had a significant deficit in total NO bioavailability.

### Ratio of H<sub>2</sub>S to NO and Vascular Disease

We next examined the relationship between plasma-free H<sub>2</sub>S and NO bioavailability as these molecules have been found to influence the other in experimental systems<sup>10</sup> which might prove informative in discriminating between different forms of vascular disease. Spearman correlation analysis between plasma NO and free H<sub>2</sub>S in all patients with vascular disease did not reveal a significant correlation. However, calculation of plasma H<sub>2</sub>S/NO concentration



**Figure 3.** Plasma-free hydrogen sulfide to total NO ratio by vascular disease. The ratio of plasma-free hydrogen sulfide to total NO was calculated per vascular disease cohort. Free H<sub>2</sub>S:NOx ratio was significantly elevated in patients with PAD alone over all other comparison cohorts, \**P*<0.05. No vascular disease n=53, CAD alone n=66, PAD alone n=13, and any vascular disease n=140. CAD indicates coronary artery disease; H<sub>2</sub>S, hydrogen sulfide; NO, nitric oxide; PAD, peripheral artery disease.

ratios was performed for each cohort and compared using linear regression analysis. Importantly, the plasma H<sub>2</sub>S/NO ratio was significantly elevated in the PAD alone group (*P*=0.031) compared to patients with CAD alone versus those without vascular disease (Figure 3). Together, these data reveal a novel finding that patients with PAD have significantly greater amounts of plasma-free H<sub>2</sub>S with respect to total NO levels.

### Discussion

H<sub>2</sub>S is a colorless, pungent gas that has multiple functions in human physiology including regulation of neurological function, intestinal inflammation, ischemia reperfusion injury,

vasomotor tone regulation, and angiogenesis.<sup>23–27</sup> A clear understanding of H<sub>2</sub>S bioavailability and metabolism has been impeded by controversies in its measurement and it is now well established that nonanalytical methods have resulted in anomalous levels.<sup>12,28,29</sup> Even accounting for data utilizing problematic methods, there still remains a paucity of information regarding plasma-free H<sub>2</sub>S levels in normal human physiology and disease states, much less its relationship to NO bioavailability.<sup>14,30</sup>

Several studies posit an important role of H<sub>2</sub>S in atherosclerosis pathogenesis involving both its development and attenuation of consequences of ischemic vascular remodeling and tissue ischemia reperfusion injury.<sup>6,31</sup> H<sub>2</sub>S has been shown to decrease oxidation of low-density lipoprotein (LDL) as well as uptake of oxidized LDL by macrophages involving antioxidant responses.<sup>6–8</sup> Furthermore, H<sub>2</sub>S impairs the migration of monocytes into the subendothelial layer via reduction of expression of ICAM-1 and monocyte chemoattractant protein-1 (MCP-1).<sup>6,32</sup> H<sub>2</sub>S has also been found to inhibit foam cell formation and vascular smooth muscle cell proliferation.<sup>6</sup> Lastly, H<sub>2</sub>S reduces vascular calcification in the rat model via down-regulation of alkaline phosphatase activity and osteopontin gene down-regulation.<sup>33</sup> Together, these findings suggest that changes in plasma-free H<sub>2</sub>S levels could affect several different pathophysiological responses involved in atherosclerotic vessel disease.

Thus, elevation of plasma-free H<sub>2</sub>S found in our study could be interpreted in different ways; with an initial explanation being a compensatory response to endothelial dysfunction and dysregulation of NO bioavailability. As mentioned previously, recent studies reveal that H<sub>2</sub>S can alter eNOS expression and function while also enhancing nitrite anion reduction to NO, thus serving as an alternate pathway for regulating NO bioavailability.<sup>9,10</sup> Interestingly, we found that plasma NO levels were significantly reduced in all patients compared to reported normal levels of NO in healthy persons, with PAD-alone subjects showing the greatest deficit confirming recent findings that plasma NO levels are critically altered during PAD.<sup>34</sup> This observation is important when considering the relationship between plasma-free H<sub>2</sub>S and NO levels such that patients with PAD had the highest levels of plasma-free H<sub>2</sub>S compared to patients with CAD. These findings suggest that vascular disease mechanisms could be different between patients with CAD versus those with PAD. Future studies will address the nature of the H<sub>2</sub>S/NO relationship differences and whether such interactions may exist in healthy adults with no or few cardiovascular risk factors.

Alternatively, elevated plasma-free H<sub>2</sub>S levels in patients with vascular disease may play a pathogenic role by decreasing NO production and bioavailability contributing to vascular dysfunction. Previous studies have shown that H<sub>2</sub>S donors (Na<sub>2</sub>S) can inhibit eNOS function and that H<sub>2</sub>S can

interact with NO metabolites to generate novel reactive species.<sup>35–37</sup> Clearly, further cause and effect studies are needed to better understand the pathophysiological implications of our findings. Moreover, additional areas of investigation involving measurement of plasma CSE and CBS enzyme expression and activity along with cysteine substrate bioavailability will also be important to determine whether these factors may contribute to different observations between disease cohorts.

Having observed distinct differences in plasma-free H<sub>2</sub>S and total NO in patients with vascular disease leads to the obvious question whether the use of such a test may serve as a biomarker for cardiovascular disease. Numerous studies have endeavored to identify useful biomarkers for vascular diseases including PAD. Multiple indicators have been examined from soluble adhesion molecules, inflammatory mediators, cytokines, and other plasma proteins.<sup>38,39</sup> However, clinical utility of these markers as an indicator of vascular disease is still not clear and is under active investigation. A recent study by Smadja et al<sup>40</sup> suggested that plasma TSP-1 levels might identify patients with PAD as TSP-1 levels were increased over control patients. In our study, we did not observe a similar increase in plasma TSP-1 levels likely due to the fact that our study included Caucasian and African American males and females in contrast to Smadja et al that enrolled only “white men younger than 70 years of age”. With regard to markers of vascular inflammation, we did not find a clear relationship or interaction of plasma-free H<sub>2</sub>S or NO levels with IL-6 or sICAM-1 levels. Future studies are clearly necessary to more closely evaluate the possibility of utilizing H<sub>2</sub>S either alone or in combination with other molecules as a biomarker for vascular disease.

We recognize that our study has limitations. First, we employed the definition of noncompressible arteries (ie, an ABI >1.3) that was recommended at the time of study design and approval. However, since that time the ABI cut-off has been increased to >1.4, though we believe this to have a minimal effect on the major finding of our study. Moreover, in the rapidly evolving field of H<sub>2</sub>S biology, our laboratory has published a new method that sensitively and accurately measures discrete biologic pools of H<sub>2</sub>S.<sup>17</sup> While we did not evaluate differences in bioavailability of H<sub>2</sub>S in different biochemical forms, a separate study is currently ongoing to measure these biochemical forms in order to gain additional insight into H<sub>2</sub>S metabolite bioavailability in different cardiovascular disease states. We do not know if there is a circadian variation in H<sub>2</sub>S levels, however since all of the procedures were performed during daytime hours, the impact of any circadian variation if any should be small and are likely to be equally distributed amongst the various groups. We also did not assess for cerebrovascular disease involvement, although this will be examined in future trials. Furthermore, inherent to

the fact that the majority of patients presented for coronary angiography and the frequent coexistence of disease in multiple vascular beds, our sample of patients with PAD alone is small. Lastly, we acknowledge that the patients studied here may not be representative of age-matched healthy subjects that will require further study to obtain a better understanding between H<sub>2</sub>S and NO bioavailability and cardiovascular disease.

In conclusion, our findings provide initial insight into plasma-free H<sub>2</sub>S and NO bioavailability during cardiovascular disease states using precise analytical measurement techniques revealing unique pathophysiologic relationships between these molecules. Our findings suggest that closer evaluation of gasotransmitter levels during cardiovascular disease could be informative from a clinical or therapeutic perspective. While our study may be viewed as hypothesis generating, larger, multicenter trials are needed to further investigate the utility of these results and to gain greater insight into the pathophysiological importance of H<sub>2</sub>S and NO bioavailability during cardiovascular disease.

## Sources of Funding

This work was funded in part by a fellowship from the Malcolm Feist Cardiovascular Research Endowment, LSU Health Sciences Center-Shreveport to Dr Peter and NIH grant HL113303 to Dr Kevil

## Disclosures

Drs Peter, Shen, and Kevil have filed provisional intellectual property on the use of gasotransmitter measurements for clinical cardiovascular disease. Dr Kevil has ownership equity of and serves as CSO for Theravasc Inc.

## References

- Kevil CG, Kolluru GK, Pattillo CB, Giordano T. Inorganic nitrite therapy: historical perspective and future directions. *Free Radical Biol Med*. 2011; 51:576–593.
- Olson KR. A practical look at the chemistry and biology of hydrogen sulfide. *Antioxid Redox Signal*. 2012;17:32–44.
- Kabil O, Banerjee R. Redox biochemistry of hydrogen sulfide. *J Biol Chem*. 2010;285:21903–21907.
- Kabil O, Banerjee R. Enzymology of H<sub>2</sub>S biogenesis, decay and signaling. *Antioxid Redox Signal*. 2013; Jun 7 [Epub ahead of print] doi: 10.1089/ars.2013.5339.
- Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, Barrow RK, Yang G, Wang R, Snyder SH. H<sub>2</sub>S signals through protein S-sulfhydration. *Sci Signal*. 2009;2:ra72.
- Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, Tang X, Ren Y, Tang C, Du J. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. *Arterioscler Thromb Vasc Biol*. 2009;29:173–179.
- Zhao ZZ, Wang Z, Li GH, Wang R, Tan JM, Cao X, Suo R, Jiang ZS. Hydrogen sulfide inhibits macrophage-derived foam cell formation. *Exp Biol Med*. 2011;236:169–176.
- Laggner H, Muellner MK, Schreier S, Sturm B, Hermann M, Exner M, Gmeiner BM, Kapiotis S. Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCL. *Free Radical Res*. 2007;41:741–747.
- Bir S, Kolluru G, McCarthy P, Shen X, Pardue S, Pattillo C, Kevil C. Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia inducible factor 1 $\alpha$  and vascular endothelial growth factor dependent angiogenesis. *J Am Heart Assoc*. 2012;1:e004093 doi: 10.1161/JAHA.112.004093.
- Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos P, Asimakopoulou A, Gero D, Sharina I, Martin E, Szabo C. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc Natl Acad Sci USA*. 2012;109:9161–9166.
- Hughes MN, Centelles MN, Moore KP. Making and working with hydrogen sulfide: the chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review. *Free Radical Biol Med*. 2009;47:1346–1353.
- Shen X, Pattillo CB, Pardue S, Bir SC, Wang R, Kevil CG. Measurement of plasma hydrogen sulfide in vivo and in vitro. *Free Radical Biol Med*. 2011; 50:1021–1031.
- Van de Louw A, Haouzi P. Oxygen deficit and H<sub>2</sub>S in hemorrhagic shock in rats. *Crit Care*. 2012;16:R178.
- Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, McVie R, Bocchini JA. Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? *Antioxid Redox Signal*. 2010;12:1333–1337.
- Wintner EA, Deckwerth TL, Langston W, Bengtsson A, Leviten D, Hill P, Insko MA, Dumpit R, VandenEkar E, Toombs CF, Szabo C. A monobromobimane-based assay to measure the pharmacokinetic profile of reactive sulphide species in blood. *Br J Pharmacol*. 2010;160:941–957.
- Shen X, Carlstrom M, Borniquel S, Jadert C, Kevil CG, Lundberg JO. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. *Free Radical Biol Med*. 2013;60C:195–200.
- Shen X, Peter EA, Bir S, Wang R, Kevil CG. Analytical measurement of discrete hydrogen sulfide pools in biological specimens. *Free Radical Biol Med*. 2012;52:2276–2283.
- Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG, Hiatt WR, Jonsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL, Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular D, Council on E, Prevention, Council on Clinical C, Council on Cardiovascular N, Council on Cardiovascular R, Intervention, Council on Cardiovascular S, Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. *Circulation*. 2012;126:2890–2909.
- Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT Jr, Drozda JP Jr, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS; American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data S, American College of Emergency P, Emergency Nurses A, National Association of Emergency Medical T, National Association of EMS/Preventive Cardiovascular Nurses A, Society for Cardiovascular A, Interventions, Society of Cardiovascular Patient C, Society of Thoracic S. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). *Circulation*. 2013;127:1052–1089.
- Unger J, Filippi G, Patsch W. Measurements of free hemoglobin and hemolysis index: EDTA- or lithium-heparinate plasma? *Clin Chem*. 2007;53:1717–1718.
- Venkatesh PK, Pattillo CB, Branch B, Hood J, Thoma S, Illum S, Pardue S, Teng X, Patel RP, Kevil CG. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. *Cardiovasc Res*. 2010;85:661–670.
- Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. *Free Radical Biol Med*. 2006;40:295–302.
- Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. *Circ Res*. 2009;105:365–374.
- Liu YH, Lu M, Hu LF, Wong PT, Webb GD, Bian JS. Hydrogen sulfide in the mammalian cardiovascular system. *Antioxid Redox Signal*. 2012;17:141–185.

25. Lavu M, Bhushan S, Lefer DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. *Clin Sci*. 2011;120:219–229.
26. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski LK, Herndon DN, Wang R, Szabo C. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc Natl Acad Sci USA*. 2009;106:21972–21977.
27. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J*. 2001;20:6008–6016.
28. Olson KR. The therapeutic potential of hydrogen sulfide: separating hype from hope. *Am J Physiol Regul Integr Comp Physiol*. 2011;301:R297–R312.
29. Olson KR. Is hydrogen sulfide a circulating “gasotransmitter” in vertebrate blood? *Biochim Biophys Acta*. 2009;1787:856–863.
30. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, Tooke JE, Shore AC. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. *Diabetologia*. 2010;53:1722–1726.
31. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev*. 2012;92:791–896.
32. Jin HF, Liang C, Liang JM, Tang CS, Du JB. Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow: experiment with rats. *Zhonghua Yi Xue Za Zhi*. 2008;88:2235–2239.
33. Wu SY, Pan CS, Geng B, Zhao J, Yu F, Pang YZ, Tang CS, Qi YF. Hydrogen sulfide ameliorates vascular calcification induced by vitamin D3 plus nicotine in rats. *Acta Pharmacol Sin*. 2006;27:299–306.
34. Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in peripheral artery disease. *Nitric Oxide*. 2012;26:217–222.
35. Filipovic MR, Miljkovic J, Nauser T, Royzen M, Klos K, Shubina T, Koppenol WH, Lippard SJ, Ivanovic-Burmazovic I. Chemical characterization of the smallest S-nitrosothiol, HSNO; cellular cross-talk of H<sub>2</sub>S and S-nitrosothiols. *J Am Chem Soc*. 2012;134:12016–12027.
36. Geng B, Cui Y, Zhao J, Yu F, Zhu Y, Xu G, Zhang Z, Tang C, Du J. Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. *Am J Physiol Regul Integr Comp Physiol*. 2007;293:R1608–R1618.
37. Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A. Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. *Toxicology*. 2007;232:138–146.
38. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. *J Am Coll Cardiol*. 2010;55:2017–2023.
39. Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis. *Nat Rev Cardiol*. 2011;8:405–418.
40. Smadja DM, d’Audigier C, Bieche I, Evrard S, Mauge L, Dias JV, Labreuche J, Laurendeau I, Marsac B, Dizier B, Wagner-Ballon O, Boisson-Vidal C, Morandi V, Duong-Van-Huyen JP, Bruneval P, Dignat-George F, Emmerich J, Gaussem P. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. *Arterioscler Thromb Vasc Biol*. 2011;31:551–559.



## Plasma Free H<sub>2</sub>S Levels are Elevated in Patients With Cardiovascular Disease

Elvis A. Peter, Xinggui Shen, Shivang H. Shah, Sibile Pardue, John D. Glawe, Wayne W. Zhang, Pratap Reddy, Nuri I. Akkus, Jai Varma and Christopher G. Kevil

*J Am Heart Assoc.* 2013;2:e000387; originally published October 23, 2013;  
doi: 10.1161/JAHA.113.000387

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://jaha.ahajournals.org/content/2/5/e000387>